chartexchange

Bright Minds Biosciences (DRUG) Securities Investigation Notice - Levi & Korsinsky

PR Newswire | Nov 9, 2026 10:09 AM EST

Bright Minds Biosciences (DRUG) shares sold off sharply as the market reacted to an FDA partial clinical hold on the planned Phase 2 BMB-101 pediatric epilepsy trial. An investigation into potential securities law violations is underway on behalf of investors who lost money. NEW YORK, Nov....

Read original article